Gensight Biologics SA (PA:SIGHT) — Market Cap & Net Worth
Market Cap & Net Worth: Gensight Biologics SA (SIGHT)
Gensight Biologics SA (PA:SIGHT) has a market capitalization of $18.36 Million (€15.71 Million) as of May 6, 2026. Listed on the PA stock exchange, this France-based company holds position #25289 globally and #414 in its home market, demonstrating a 3.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gensight Biologics SA's stock price €0.09 by its total outstanding shares 220463002 (220.46 Million). Analyse Gensight Biologics SA (SIGHT) cash conversion ratio to see how efficiently the company converts income to cash.
Gensight Biologics SA Market Cap History: 2016 to 2026
Gensight Biologics SA's market capitalization history from 2016 to 2026. Data shows change from $2.00 Billion to $21.50 Million (-37.18% CAGR).
Index Memberships
Gensight Biologics SA is a constituent of 7 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$230.90 Billion | 0.01% | #105 of 119 |
|
CAC Small90
CACS
|
$35.46 Billion | 0.05% | #54 of 64 |
|
CAC All-Tradable
CACT
|
$2.86 Trillion | 0.00% | #165 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.86 Trillion | 0.00% | #165 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.86 Trillion | 0.00% | #165 of 179 |
|
CAC PME
CAPME
|
$35.27 Billion | 0.05% | #26 of 34 |
|
CAC Health Care
FRHC
|
$257.53 Billion | 0.01% | #30 of 36 |
Weight: Gensight Biologics SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Gensight Biologics SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gensight Biologics SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
26.51x
Gensight Biologics SA's market cap is 26.51 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.00 Billion | $3.00 Million | -$22.08 Million | 665.62x | N/A |
| 2017 | $1.59 Billion | $3.70 Million | -$24.11 Million | 430.27x | N/A |
| 2018 | $858.29 Million | $4.35 Million | -$33.45 Million | 197.49x | N/A |
| 2019 | $640.49 Million | $700.00K | -$30.71 Million | 914.99x | N/A |
| 2020 | $1.84 Billion | $4.39 Million | -$34.02 Million | 418.23x | N/A |
| 2021 | $1.43 Billion | $5.28 Million | -$28.62 Million | 271.62x | N/A |
| 2022 | $866.54 Million | $2.58 Million | -$27.62 Million | 335.61x | N/A |
| 2023 | $118.56 Million | $1.27 Million | -$26.22 Million | 93.58x | N/A |
| 2024 | $69.59 Million | $2.62 Million | -$14.00 Million | 26.51x | N/A |
Competitor Companies of SIGHT by Market Capitalization
Companies near Gensight Biologics SA in the global market cap rankings as of May 6, 2026.
Key companies related to Gensight Biologics SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Gensight Biologics SA Historical Marketcap From 2016 to 2026
Between 2016 and today, Gensight Biologics SA's market cap moved from $2.00 Billion to $ 21.50 Million, with a yearly change of -37.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €21.50 Million | -20.11% |
| 2025 | €26.91 Million | -61.33% |
| 2024 | €69.59 Million | -41.30% |
| 2023 | €118.56 Million | -86.32% |
| 2022 | €866.54 Million | -39.53% |
| 2021 | €1.43 Billion | -22.02% |
| 2020 | €1.84 Billion | +186.92% |
| 2019 | €640.49 Million | -25.38% |
| 2018 | €858.29 Million | -46.12% |
| 2017 | €1.59 Billion | -20.26% |
| 2016 | €2.00 Billion | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Gensight Biologics SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $18.36 Million USD |
| MoneyControl | $18.36 Million USD |
| MarketWatch | $18.36 Million USD |
| marketcap.company | $18.36 Million USD |
| Reuters | $18.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Gensight Biologics SA
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV… Read more